Phio Pharmaceuticals Corp（PHIO）财务数据PHIOPhio Pharmaceuticals Corp

Evaluating the bottom line, Phio Pharmaceuticals Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -113.71%, provide a clear picture of how effectively PHIO converts its operational activities into shareholder value.

In the context of the broader market, PHIO competes directly with industry leaders such as BNGO and INTS. With a market capitalization of $12.66M, it holds a significant position in the sector. When comparing efficiency, PHIO's gross margin of N/A stands against BNGO's 52.80% and INTS's N/A. Such benchmarking helps identify whether Phio Pharmaceuticals Corp is trading at a premium or discount relative to its financial performance.

Phio Pharmaceuticals has reported consistent losses, with net income losses increasing to -4,138,000 USD in Q2 2026. The company has a current ratio of 0.00 in Q2 2026, indicating potential liquidity issues, despite having a cash position of approximately $21.0 million as of December 31, 2025.